DSM Venturing

We obsess over the values shifts driving consumers and the tech shifts underpinning consumer adoption. The need and potential is clear, and the opportunities are massive.Evolved attitudes and social norms are shaping new demands. Antiquated and fragile systems are begging for reinvention. Ongoing demographic shifts are fueling deep, fundamental needs. The power of technology for progress is more profound and scalable than ever.We live in a society dependent on thoughtful bridging of on-and off-line worlds. Generative AI will unlock a new set of possibilities. Nimble adoption and swift, bold change is the norm. We believe opportunity lies ahead of the trend. In an industry obsessed with trailblazing, we go one step further: We meet the consumer where they’re going. When big thinkers are poised to transform culture, they become more than just founders, or CEOs, or investors, or entrepreneurs. They become Forerunners.Forerunner Advantage Forerunner is a research-focused, thesis-driven venture capital firm that’s dedicated to serving a fast-changing society with complex needs. We believe in walking the walk: early action, high conviction, engaged partnership. Research-focused: We commit ourselves to having a constant pulse on what people are doing and why. This requires both IQ and EQ - we combine data-driven research with an intimate understanding of peoples’ needs. We always show up with a prepared mind. Thesis-driven: We leverage our research to uncover business opportunity and invest in the teams best positioned to reshape categories and help transform culture, such as Faire, Chime, Glossier, Hims&Hers, ŌURA, The Farmer’s Dog, Ritual, and more. And the work doesn’t stop when we invest. Consumer-led: The consumer is our North Star. We invest to support evolving societal needs and further the potential of people. We see technology-driven change as a means to meet the consumer - your user - where they are going. Credibility-building: Working with us is a statement about the company you aim to build. Our focused efforts and decades-long track record of partnering with category-defining companies early have established Forerunner as a true advantage to founders.

Venture capital for environmental health and healthcare infrastructure startups tackling the root causes of why we get sick. Root Causes Man perisheth. That may be, but let us struggle even though we perish; and if the nothing is to be our portion, let it not come to us as a just reward. – Senancour By some estimates, between 70-90% of chronic diseases are driven, at least in part, by our environmental exposures. [1] As the world has industrialized, toxic exposures have increased, which has translated to rising prevalence rates of chronic diseases both here in the US and around the globe. 42% of Americans now suffer from 2 or more chronic conditions. [2]​ The good news is we have the power to bend this curve. While we can’t do much to change the fundamentals of our genetics, we can change our environment. As more and more people have started to recognize environmental exposures are root cause drivers of ill health, more technologists and scientists are stepping up to help us fight this rising tide of disease. Our sole mission at MBX is to back these leaders. So what has to get done? First, we have to clean up our environment - our water, our air, our soil, our built environment, our food, and so on - with a laser focus on the things that pose the greatest risk of toxicity to us. We know there aren't abundant resources for clean up, so to do this, we have to create cheaper and better ways to abate pollutants than ever before. Second, we need to replace legacy, hazardous chemicals and materials with safer, bio-inert ones. To be clear, we don’t believe all chemicals are bad - they’re not. Novel chemicals have unlocked abundance that has reduced rates of hunger, driven economic progress, and alleviated global poverty. We need highly functional chemistries to support the transition to renewable energy, to protect our food supplies, treat our illnesses, and much more. The opportunity going forward lies in harnessing the techniques of green chemistry and advances in safety toxicology to design products that are bio-inert, or at the very least, products which present lower risks to our health. Third, we have to harness data from our environmental exposures (the cumulative set of which make up our exposomes) to develop new medicines and diagnostics - we call this exposomic medicine. There are now powerful technologies for analyzing our in vivo chemical exposures, and we can use this exposure data to pinpoint the mechanisms of diseases we today don’t understand well. This information has great potential to enable the next generation of biotech companies to make immense progress on previously intractable diseases, such as many cancers and neurodegenerative conditions. Finally, but no less importantly, we have to adapt our healthcare infrastructure to deal with the rising burden of disease. It will take time to clean up our environment, replace chemicals, and advance exposomic medicine. In the meantime, we need to fortify our existing system of healthcare by arming our limited supply of healthcare providers with technology that gives them more time and tools to treat an ever growing number of patients, especially in underserved communities. We know none of this is easy, but with ingenuity and dedication, we believe there’s great progress to be made. We’re up for the challenge - are you? Frequently Asked Questions What sectors do you invest in? We're agnostic to sector as long as your company is addressing a clear root cause problem. Whether you're building a deep-tech or biotech company or focused on healthcare delivery, as long as you can make durable progress towards improving human health, we can back you. Our portfolio includes companies doing everything from pollutant abatement to developing new medicines and diagnostics to making healthcare more accessible for underserved communities. What rounds do you invest in? We usually invest in the first or second institutional round of financing that a company raises, and typically before companies have reached a $50mm valuation. In practice, this means we usually invest in Seed and early Series A financings. How much do you typically invest? Our typical first check is usually between $1 to 2.5mm, though we can flex up or down from this depending on the stage of the company. We generally seek at least 5% ownership when we invest. Do you lead investments? While we prefer to lead or co-lead financings, we can also participate as a follow-on investor. Where do you invest? Most of our investments are in the United States, but we can invest anywhere in the world for the right opportunity. How do you help your partner companies? There are hundreds of leading scientists, clinicians, and industry executives in the MBX Atom Network. This enables us to match our companies to relevant domain experts who can unlock customer relationships and provide tactical advice throughout their journeys. What are your Assets Under Management? As of 6/4/24, our AUM was in excess of $100mm.

K2HV’s investment professionals bring together substantial experience across multiple verticals in healthcare finance and operations, as well as considerable scientific knowledge. Our diverse backgrounds and experience give us a deep understanding of the needs of innovative healthcare companies throughout their lifecycles, and underpin our innovative and creative approach to investing. Our leadership team has committed more than $4 billion to over 100 private and public companies in the life sciences and healthcare industries. High Impact Investments, Long-Term ViewUniquely flexible, permanent capital structure enables us to provide long-term financing solutions and meet the evolving capital needs of growing companies Broad investment mandate allows us to be creative with financing structures Primary focus on customized debt financings, but able to invest in equity as well

Noetic invests globally to build emerging technologies in molecular therapeutics/biotech, digital health, medical devices, and wellness with a focus on mental health, pain, and other complications resulting from the central nervous system. About no•et•ic “From the Greek noēsis/ noētikos meaning inner wisdom, direct knowing, or subjective understanding” Noetic science refers to a multidisciplinary field that brings objective scientific tools and techniques together with subjective understanding to study the full range of human experience. Mission: Our mission is to nurture the scientific advancement of mental, emotional, and physiological health by investing in emerging therapies, modalities, and sciences that are committed to optimizing our human experience. Commitment: We are committed to developing sustainable therapies, products, and services that are innovative, safe, and accessible to create a better mental health landscape for current and future generations. Focus: CNS-targetted therapeutics and related sustainable solutions for mental health and physical well being.

Cathay Health is dedicated to investing in companies at the convergence of life sciences, healthcare and technology with positive impact on human health. With a reach spanning key bio and tech hubs around the globe, we help companies scale across borders and access new markets, partners and patients. Our Strategy We back venture- and growth-stage companies with emerging technologies that catalyze groundbreaking advances in healthcare. We fund future leaders in tech-enabled medicine with differentiated approaches and strong intellectual property to personalize care, improve access and lower cost. We invest in Series A to C rounds with the ability to lead or co-invest, and help companies scale across borders. Our Focus AreasLife Science Tools Diagnostics Clinical Trial Innovation New Care Models Novel Devices & Materials Enabling Technologies For Advanced Therapies Why Cathay HealthA global platform catalyzing cross-industry collaboration: Cathay Health is affiliated to Cathay Capital – a global investment platform connecting partners and catalyzing collaborations across Europe, North America and Asia to solve the world’s most pressing challenges. Scaling companies to transform health across borders: Our global network and operating expertise across regions allows us to grow impactful companies that serve patients worldwide. Deep expertise in both healthcare and technology: Our unique expertise allows us to identify investment opportunities with the largest impact on human health and care. Investing & operating at the convergence Our team not only invests – but brings operating experience – at the convergence of life sciences, healthcare and tech. Our expertise uniquely bridges these complementary fields to maximize the potential of our portfolio companies.

라플라스파트너스는 초기 단계 기술 기업들의 성장을 돕는 것을 소명으로 여기며, 시장을 확장하는 등 강한 목적의식을 가진 스타트업들과 협력하고 싶습니다. 비전 어떤 문제를 해결하고 세상에 어떤 변화를 가져오고 싶은지, 즉, 미래에 대한 명확한 비전을 그릴 수 있는 팀을 기대합니다. 이유 세상의 많은 문제들 중 왜 ‘그 문제’를 해결하고 싶은지에 대해 납득할 만한 이유가 있는 팀을 선호합니다 가치 ‘비전’과 ‘이유’를 바탕으로 고객에게 얼마나 유의미한 가치를 제공할 수 있는가에 집중합니다. 혁신 기술 라플라스파트너스는 혁신 기술로 문제를 해결하고 새로운 패러다임을 만들어가는 영역에 투자합니다. 바이오·헬스케어 제약, 혁신 진단 기기, 디지털 헬스케어, 건강 기능 식품, 푸드테크 등 소재·부품·장비 2차 전지, 반도체 소재·장비, 에너지, 신소재, 디스플레이, 통신 등 IT 인공지능(AI)의 응용, 전기차, 자율주행, 로봇, 메타버스, 증강현실(AR) 등